The impact of normalization of esophageal acid profile by incremental protein pump inhibitors dosing in difficult asthma patients with proven gastro-esophageal acid reflux

Journal of Asthma

Volumn 46, Issue 5, 2009, Pages 506-511

  Bucknall, Christine ^a,b   Stanton, Andrew ^a   Miller, Graham ^b   Rajoriya, Neil ^a   Babu, Suresh ^b   MacKenzie, John ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b STOBHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZELASTINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CLARITHROMYCIN; CORTICOSTEROID; ESOMEPRAZOLE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; LANSOPRAZOLE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHOTREXATE; MOMETASONE FUROATE; MONTELUKAST; PANTOPRAZOLE; PREDNISOLONE; PROTON PUMP INHIBITOR; SALBUTAMOL; SALMETEROL XINAFOATE; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE;

ADULT; AGED; ARTICLE; ASTHMA; CORTICOSTEROID THERAPY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ESOPHAGUS PH; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL REFLUX; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; SCORING SYSTEM; TREATMENT OUTCOME; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; ESOPHAGUS; MIDDLE AGED; PATHOPHYSIOLOGY; PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGUS; FEMALE; GASTROESOPHAGEAL REFLUX; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED;

EID: 67650333902     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900902866784     Document Type: Article

References (23)

1. Stanghellini V. Three month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/ International Gastroenterology Surveillance study (DIGEST) Scand J Gastroenterol 1999; 34(suppl 231):20-28.
2. Kiljander TO, Laitinen JO. The prevalence of gastroesophageal reflux disease in adult asthmatics. Chest 2004; 126:1398-41403.
3. Legget JL, Johnston BT, Mills M, Gamble J, Heaney L. Prevalence of gastroesophageal reflux in difficult asthma. Chest 2005; 127:1227-1231.
4. Ten Brinke A, Sterk PJ, Masclee AAM, Spinhoven P, Schmidt JT, Zwinderman AH, Rabe KF, Bel EH. Risk factors of frequent exacerbations in difficult to treat asthma Eur Resp J 2005; 26:812-818.
5. Coughlan JL. Gibson PG, Henry RL. Medical treatment for reflux oesophagitis does not consistently improve asthma control: a systematic review. Thorax 2001; 56:198-204.
6. Gibson PG, Henry RL, Coughlan JL. Gastro-oesophageal reflux treatment for asthmainadults and children. Cochrane DatabaseofSystematic Reviews 2003, Issue 1. Art CD001496. DOI: 10.1002/14651858.CD001496.
7. The BTS/SIGN British Guideline on the Management of Asthma April 2004 Update Thorax 2003; Vol 58(supplement 1).
8. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2007. Available from http://www.ginasthma. org
9. Harding SM, Guzzo MR, Richter JE. The prevalence of Gastroesophageal reflux in asthma patients without reflux symptoms. Am J Respir Crit Care Med 2000; 162:34-39.
10. Kiljander TO, Salomaa EM, Hietanen EK, Terho EO. Gastroesophageal Reflux in Asthmatics. A double-blind, placebo-controlled crossover study with omeprazole. Chest 1999; 116:1257-1264.
11. Everett CF, Kastelik JA, Mulrennan SA, Morice AH. CommentofPredictors of therapy resistant asthma. Thorax 2004; 59:270-271.
12. Harding SM, Richter JL, Guzzo MR, Schan CA, Alexander RW, Bradley LA. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am J Med 1996; 100:395-405.
13. Kiljander TO, Harding SM, Field SK, Stein MR, Nelson HS, Ekelund J, Illueca M, Becknam O, Sostek MB. Effects of Esomeprazole 40 mg twice daily on asthma, a randomized placebo-controlled trial. Am J Resp Crit Care Med 2006; 173:1091-1097.
14. Irwin RS, Curley FJ, French CL. Difficult to control asthma: contributing factors and outcome of a systematic management protocol. Chest 1993; 103:1662-1669.
15. British Society of Gastroenterology Guidelines for oesophageal manom-etry and pH monitoring. September 1996, updated November 2006 http://www.bsg.org.uk
16. Johnson LF, De Meester TR. Twenty-four hour pH monitoring of the distal oesophagus. Am J Gastroenterol 1974; 62:325-332.
17. Stanton AE,Vaughn P, Bucknall CE. An observational investigation of hyperventilation and breathing control in a Problem Asthma Clinic. Thorax 2005; 60 (suppl 2):ii42.
18. Alexander JA, Hunt LW, Patel AM. Prevalence, pathophysiology and treatment of patients with asthma and gastroesophageal reflux disease. Mayo Clin Proc 2000; 75:1055-1063.
19. Gislason T, Janson C, Vermeire P, Plaschke P, Bjornsson E, Gillason D, Boman G. Respiratory symptoms and nocturnal gastroesophageal reflux. Chest 2002; 121:158-163.
20. Taylor B, Mannino D, Brown C, Crocker D, Twum-Baah N, Holguin F. Body mass index and asthma severity in the National Asthma Survey. Thorax 2008; 63:14-20.
21. Farrokhi F, Vaezi MF. Extra-esophageal manifestations of gastroesophageal reflux. Oral Dis 2007; 13:349-359.
22. Galmiche JP. Non erosive reflux disease and atypical gastro-oesophageal reflux disease manifestations: treatment results. Drugs 2006; 66 suppl 1:7- 13.
23. Kiljander T, Salomaa ER, Heeitanen E, Helenius H, Liippo K, Terho EO. Asthma and gastro-oesophageal reflux: can the response to anti-reflux therapy be predicted? Resp Medicine 2001; 95:387-392.